How Geneticists Reclassify an ALPL Variant of Uncertain Significance (VUS): Your Diagnostic Next Step

When genetic testing for hypophosphatasia or related conditions flags an ALPL variant of uncertain significance (VUS), it means we don’t yet know whether that change in the ALPL gene causes disease. Reclassifying a VUS into a benign or pathogenic category is a stepwise process involving clinical data, laboratory testing, family studies, and expert guidelines. Below is a clear roadmap for patients and clinicians navigating this journey.

---

1. Gather Detailed Clinical and Biochemical Data

Even before digging into genetic databases, start by confirming the patient’s symptoms and biochemical profile. This real-world context is essential to weigh whether the ALPL VUS might explain the clinical picture.

• Document all relevant signs and symptoms

• Bone pain, fractures, or delayed tooth development
• Muscle weakness, fatigue, or gait abnormalities
• Neuropsychiatric issues such as irritability or seizures in infants

• Order key laboratory tests

• Serum alkaline phosphatase (ALP) activity (low levels raise suspicion)
• Serum pyridoxal-5′-phosphate (PLP; elevated in hypophosphatasia)
• Calcium, phosphate, and vitamin D levels

• Compare results to age- and sex-matched reference ranges

• Young children and adolescents normally have higher ALP than adults
• Mildly reduced ALP may be less specific; very low ALP is more concerning

---

2. Review Population and Disease Databases

Next, assess how common the VUS is in the general population versus in people diagnosed with hypophosphatasia.

• Consult allele frequency resources

• gnomAD (Genome Aggregation Database):
  – Variants with a frequency above ~0.1% in healthy populations are unlikely to be highly pathogenic
• ExAC and 1000 Genomes as supplementary checks

• Check disease-specific repositories

• ClinVar: May list previous submissions classifying the same variant
• ALPL locus-specific databases (if available): Often curated by research consortia

• Note discrepancies or consensus

• If multiple labs report conflicting interpretations, further study is definitely needed

---

3. Apply ACMG/AMP Variant Classification Criteria

The American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP) have established a robust framework for classifying variants. Matching your evidence against these standardized rules helps ensure consistency.

1. Population Data (BS1/PM2)

   • BS1 (Benign Strong): Too common in controls
   • PM2 (Pathogenic Moderate): Absent or extremely rare in controls

2. Computational and Predictive Data (BP4/PP3)

   • BP4 (Benign Supporting): Multiple computational tools predict no impact
   • PP3 (Pathogenic Supporting): Multiple tools predict damaging effect

3. Functional Studies (PS3/BS3)

   • PS3 (Pathogenic Strong): Well-validated in vitro or in vivo functional assays show a deleterious effect on protein function
   • BS3 (Benign Strong): Functional studies show no impact

4. Segregation and De Novo Data (PP1/PS2)

   • PP1 (Pathogenic Supporting): Co-segregation with disease in multiple family members
   • PS2 (Pathogenic Strong): Variant arises de novo (new in the patient) with confirmed parentage

5. Allelic Data (PM3)

   • Particularly relevant for compound heterozygous cases: Two variants in trans configuration strengthen the case for pathogenicity

Combining one or more pathogenic criteria with the absence of benign criteria (or vice versa) leads to a final classification: benign, likely benign, VUS, likely pathogenic, or pathogenic.

---

4. Conduct Functional Assays (If Feasible)

For an ALPL VUS, functional studies often offer the strongest evidence:

• Enzyme Activity Assays

• Measure tissue-nonspecific alkaline phosphatase activity in patient fibroblasts or transfected cell lines
• Compare to wild-type controls

• Protein Expression and Localization

• Western blot or immunofluorescence to assess protein stability and trafficking

• Rescue Experiments

• Demonstrate whether introducing a normal ALPL copy restores enzyme activity

Partnering with a molecular genetics lab experienced in ALPL functional assays can be invaluable. Negative or inconclusive results may still help tip the ACMG scale toward benign.

---

5. Perform Family Segregation Analysis

Tracking how the VUS behaves in relatives sheds light on its clinical impact:

• Test affected and unaffected family members

• Co-segregation of the variant with low ALP levels or clinical features supports pathogenicity
• Presence of the variant in truly asymptomatic, biochemically normal relatives leans toward benign

• Document inheritance patterns

• Hypophosphatasia is autosomal recessive or dominant with variable expressivity
• Identifying a second ALPL variant in trans strengthens a recessive diagnosis

Even a small pedigree can offer useful clues. Work with a genetic counselor to collect accurate family histories and coordinate testing.

---

6. Integrate All Evidence and Seek Expert Consensus

Once clinical, biochemical, database, computational, functional, and segregation data are assembled, reconvene with your genetics team.

• Use a multidisciplinary variant review board

• Clinical geneticists, molecular pathologists, bone specialists, and genetic counselors
• Apply ACMG rules uniformly

• Document your classification rationale

• Cite each piece of evidence and how it aligns with ACMG criteria
• Prepare a report that clearly states whether the variant is now “likely pathogenic,” “likely benign,” or remains a VUS

• Consider submitting your findings to ClinVar

• Enriches public knowledge and may help other families

---

7. Communicate Results and Next Steps to the Patient

Clear, empathetic communication is crucial when updating a patient about a reclassified variant.

• If reclassified as likely pathogenic or pathogenic:

• Discuss targeted surveillance (bone density scans, dental evaluations)
• Explore treatment options (enzyme replacement therapy in eligible cases)
• Offer family member testing

• If reclassified as likely benign or benign:

• Reassure that this variant is unlikely to drive disease
• Continue monitoring symptoms through standard pediatric or adult care

• If still a VUS:

• Explain that ongoing research may eventually clarify its significance
• Emphasize the importance of reporting new symptoms or lab changes

At any point, you might consider a free, online symptom check, using the doctor approved Ubie Symptom Checker to help track and discuss emerging signs or concerns—especially if you notice changes in bone health, tooth development, or muscle strength.

---

8. Provide Ongoing Support and Safety Net

Reclassifying a variant can be a months-long process. Keep communication lines open:

• Schedule periodic follow-up appointments
• Encourage patients to stay informed about new hypophosphatasia research
• Advise immediate medical attention for any potentially life-threatening signs, such as severe bone fractures, acute muscle weakness, or seizure activity

Important: Always speak to a doctor if you experience serious or worrying symptoms. Laboratory and genetic results complement—but do not replace—the guidance of an experienced clinician.

---

By following these steps, geneticists and clinicians work together to move an ALPL VUS toward a clearer classification, guiding personalized care and reducing uncertainty for patients and their families.